NCT00252850已完成1 期
A Phase I, Open-Label Study of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin[NTN] to Assess the Safety and Tolerability of Intrastriatal Delivery to Subjects With Idiopathic Parkinson's Disease
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 12
- 试验地点
- 4
研究概览
简要总结
This is a Phase I dose escalating open-label study designed to assess the safety, tolerability and biologic activity of an in vivo AAV2 mediated delivery of the gene encoding NTN (CERE-120).
Twelve (up to 18) subjects will receive one of two open-label doses of CERE-120 via bilateral stereotactic injections targeting the putaminal region of the brain. Subjects will be enrolled in one of two cohorts, a low-dose cohort of six subjects followed by a high dose cohort of six subjects.
The design of this study is such that the primary objective, the evaluation of safety and tolerability, will be assessed by frequent observations for adverse events, clinical laboratory test results, imaging (MRI), neuropsychometric testing, and evaluations of disease status.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 35 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of bilateral idiopathic Parkinson's Disease of at least 5 years duration since diagnosis with motor fluctuations, despite adequate oral antiparkinsonian therapy.
- •Diagnosis of moderate to severe Parkinson's Disease based on clinical rating scales.
- •Males or nonpregnant females 35-75 years of age, inclusive.
- •Stable medication requirements, and clear response to antiparkinsonian medications during the 60-day eligibility evaluation period.
- •No conditions that would render the subject unsuitable for surgery, or that would interfere with any of the assessments of safety or efficacy in this trial.
- •Subject's informed consent prior to the performance of any study-specific procedure.
排除标准
- •A history of any clinically significant medical, psychiatric, or laboratory abnormality for which participation in the study would pose a safety risk to the subject.
- •History of treatment of Parkinson's disease by any procedure involving intracranial surgery or implantation of a device.
- •MRI of the brain within 12 months before the anticipated dosing procedure that indicates the presence of an abnormality that may interfere with the assessments of safety or efficacy or would, in the judgment of the investigator, present a surgical risk to the subject.
- •Any disorder that precludes a surgical procedure or alters wound healing.
- •A score of less than or equal to 25 on the Folstein Mini-Mental examination performed during the eligibility evaluation period.
- •Chemotherapy, cytotoxic therapy, or immunotherapy within 6 weeks prior to CERE-120 administration.
- •Vaccinations within 30 days prior to CERE-120 administration.
- •History, within two years before the anticipated dosing procedure, of drug or alcohol abuse.
- •Treatment with nonantiparkinsonian agents that may affect symptoms of Parkinson's disease within 60 days before the anticipated dosing procedure.
- •Any medical disability that would interfere with the assessment of safety and efficacy in this trial or would compromise the ability of the subject to undergo study procedures (e.g. MRI, PET) or to give informed consent.
- •History of prior gene transfer therapy.
- •Treatment with an investigational agent within 60 days before the anticipated dosing procedure.
研究者
研究点 (4)
Loading locations...
相似试验
已完成
1 期
A Phase I Study of CS1002 in Subjects With Advanced Solid TumorsAdvanced Solid TumorNCT04338724CStone Pharmaceuticals6
已完成
1 期
A Study of GDC-0853 in Patients With Resistant B-Cell Lymphoma or Chronic Lymphocytic Leukemia.Lymphocytic Leukemia, Chronic, Diffuse Large B-Cell LymphomaNCT01991184Genentech, Inc.24
已完成
1 期
A Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-T-cell Immunoreceptor With Ig and ITIM Domains (TIGIT) Monoclonal Antibody Injection (IBI939) in Subjects With Advanced Malignant TumorsAdvanced MalignanciesNCT04353830Innovent Biologics (Suzhou) Co. Ltd.34
招募中
1 期
A Study Evaluating the Safety, Tolerability, and Initial Efficacy of IBI110 in Subjects With Advanced Malignant TumorsAdvanced MalignanciesNCT04085185Innovent Biologics (Suzhou) Co. Ltd.268
终止
1 期
A Study for AR100DP1 in Mild to Moderate Atopic Dermatitis (AD)Dermatitis, AtopicNCT04220411Arjil Pharmaceuticals LLC17